United Kingdom · Question · Written question
UIN 203129
NHS: Drugs
Introduced
17 October 2023
Last action
20 October 2023 · Answer
Status
Answered
Sponsors
—
Subjects
Discovery layer
Source updated
20 October 2023
Summary
To ask the Secretary of State for Health and Social Care, with reference to paragraph 16 of Annex B of the Impact Assessment for the Statutory Scheme – Branded Medicines Pricing, what the evidential basis is for the assessment that the resources deployed
This text is taken from the official record. PoliticalRepo does not editorialize.
Timeline
17 October 2023
Written question
To ask the Secretary of State for Health and Social Care, with reference to paragraph 16 of Annex B of the Impact Assessment for the Statutory Scheme – Branded Medicines Pricing, what the evidential basis is for the assessment that the resources deployed
Source: Commons
20 October 2023
Answer
The approach to assessing the potential impacts on investment within the statutory scheme’s impact assessment followed well established precedent and is in-line with the Green Book paragraphs 6.5 and 6.6. As such the impact assessment considers spill-over...
Source: Written answer
Votes
No vote records are attached yet.
Versions
No version snapshots stored. Document URLs remain at the source.
Documents
No documents linked.
Sponsors
- · Department of Health and Social Care · Answering body
Related records
No cross-record relationships stored yet.
Sources
PoliticalRepo is an index and interpretation layer, not the authoritative legal source.
- Official source: https://questions-statements.parliament.uk/written-questions/detail/2023-10-17/203129
- Open data entity: https://questions-statements-api.parliament.uk/api/writtenquestions/questions/1665262
- uk · wq-1665262 · source updated 20 October 2023